The CHS/Pfizer Care until Cure Research Program
The CHS/Pfizer Care until Cure Research Program funds innovative Canadian research by the Canadian Hemophilia Society to improve understanding and treatment of inherited bleeding disorders.
Funder: Canadian Hemophilia Society
Due Dates: November 28, 2026 (Annual application deadline)
Funding Amounts: Up to $75,000/year per project; maximum $150,000 over 2–3 years
Summary: Supports Canadian research on medical and psychosocial aspects of bleeding disorders to improve understanding, treatment, and quality of life.
Description
The CHS/Pfizer Care until Cure Research Program, a partnership between the Canadian Hemophilia Society and Pfizer Canada, funds clinical, basic science, and psychosocial research on inherited bleeding disorders. The initiative targets hemophilia, von Willebrand disease, other rare bleeding disorders, and related conditions such as HIV or hepatitis C in affected populations. The program's goal is to advance understanding, management, and quality of life for people living with bleeding disorders in Canada by supporting impactful research projects.
Areas of interest include (but are not limited to):
- Epidemiology, burden of disease, and outcome research in hemophilia A or B
- Real-world observational data and patient-reported outcomes
- Personalized treatment and clinical monitoring strategies
- Basic science related to gene therapy, TFPI, and anti-TFPI monoclonal antibodies
- Antifibrinolytic therapy and innovative clinical approaches
- Special populations (e.g., adolescents, carriers, aging)
- Outcome evaluation and health economics
The program encourages multidisciplinary and innovative research that can inform better care and outcomes for affected individuals.
